// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Transition in Work Status and Quality of Life in People with Inflammatory Arthritis

Wiebke Bartels - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort

Stephanie Gottheil - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Glucocorticoid

Trigeminal Neuralgia in Systemic Sclerosis

Nancy Maltez - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Tumor Necrosis Factor Inhibitors for Sarcoidosis

Stefanie Wade - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Certolizumab pegol

Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre

Sasha Bernatsky - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains

Gabriela L. Maica - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis

Catherine E. Najem - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen

Arielle Mendel - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Using PROs to Guide Patient-Centered Conversations and Care in Inflammatory Arthritis: The Clinician Perspective

Susan J. Bartlett - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE

Pinar Ozge Avar Aydin - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus

Hermine I. Brunner - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab

Laura C Coates - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

Ustekinumab

Validation of Online Calibration Modules for the Spondyloarthritis Research Consortium of Canada MRI Scores Based on Real-Time Experiential Learning

Matthew Maksymowych - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies

David Salem - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Stroke and Myocardial Infarction Risk among Newly Diagnosed Heart Failure Patients with Reduced, Borderline, and Preserved Left Ventricle Ejection Fraction

Gregg C. Fonarow - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Trastuzumab Associated Left Ventricular Dysfunction: Can we Predict the Need for Treatment Interruption and does Interruption Affect Cardiovascular or Oncologic Outcomes?

Jordan D. Gibson - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Trastuzumab

Most Admissions to HF Service are Preceded by a Provider Interaction That Did Not Prevent Hospitalization

Maya H. Barghash - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF

Ankeet S. Bhatt - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nesiritide

Cardiac Management and Long-Termfollow-Up of Breast Cancer Patients Who Develop Mild Left Ventriculardysfunction While on Trastuzumab Therapy

Ren Jie Robert Yao - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Trastuzumab

A novel serum biomarker identifying Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

D. Chatterjee - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved